Mushrooms and Postprandial Blood Sugar: Research Review

Mushrooms & Diabetes / Blood Sugar

10–15 glycemic index

Mushrooms have a glycemic index of 10–15, far below the 55 threshold for low-glycemic foods. Two human crossover trials published in 2022 tested mushroom powder added to a meal: one lowered the post-meal glucose curve, the other left glucose unchanged but raised the satiety hormone GLP-1 and reduced hunger. This is the only mushroom-specific human evidence on the question.

Németh et al., Int J Mol Sci, 2025

~2g fiber

per cup of raw mushrooms, primarily as soluble beta-glucan

2 trials

human crossover RCTs (2022) testing mushroom powder added to a meal

3 mechanisms

viscosity, enzyme inhibition, and prebiotic gut bacteria effects

Németh et al., Int J Mol Sci, 2025

View as image ↗

Mushrooms are among the lowest-glycemic foods available. Adding them to a meal may also influence how blood sugar and appetite behave in the hours after eating, based on evidence that rarely surfaces in consumer health coverage: two human crossover trials from 2022 that tested mushroom powder added to food and measured postprandial responses directly. These are the only human trials specifically examining mushrooms at a meal and post-meal blood sugar, and their results are more nuanced than a simple "mushrooms lower blood sugar" headline. One trial reduced the post-meal glucose curve; the other did not move glucose at all but raised a satiety hormone and reduced hunger. This article covers exactly what each study found, the three mechanisms behind the effects, and the honest limits of what the evidence can and cannot claim.

For the broader context of mushroom compounds and blood sugar control across species, Mushrooms for Type 2 Diabetes: A Research-Based Guide to Evidence and Species covers the full evidence landscape.

Mushroom Glycemic Index: Why Mushrooms Themselves Don't Spike Blood Sugar

The glycemic index (GI) measures how quickly a food raises blood glucose on a scale of 0 to 100, with pure glucose at 100. Foods above 70 are considered high-glycemic; foods below 55 are considered low-glycemic; foods below 35 are considered very low-glycemic.

Mushrooms score approximately 10–15 on the glycemic index. This is among the lowest values measured for any food. The primary reason is their macronutrient composition: a full cup of raw mushrooms contains roughly 2–3 grams of total carbohydrate, of which approximately 1–2 grams is fiber. The net digestible carbohydrate per serving is so low that the glycemic impact is negligible.

This baseline fact matters for two reasons. First, it confirms that eating mushrooms as a food is not a blood sugar concern for people with diabetes or insulin resistance. Second, it frames what mushroom research is actually investigating: not just whether mushrooms themselves are safe to eat, but whether their fiber and polysaccharide content can actively reduce blood sugar spikes from other foods in the same meal.

That second question is the more interesting one, and it has different evidence. A 2025 review by Németh and colleagues at Semmelweis University described four mechanisms through which common edible mushrooms reduce insulin resistance: gut microbiome remodeling, decreased intestinal glucose absorption, lowered serum glucose, and increased GLUT4-mediated cellular glucose uptake.^[1] The decreased intestinal glucose absorption mechanism is the one most relevant to postprandial effects, and it is the one that mushroom fiber acts on most directly.

The Two Human Trials, and What Each One Actually Found

Both trials were published in 2022, both used human participants, and both measured what happens after a meal that includes mushroom powder. But they did not find the same thing, and the difference is the honest heart of this topic. These two studies are rarely surfaced in consumer health coverage, and when they are, the null glucose result of the first is usually omitted.

The Two 2022 Human Meal Trials

Same Idea, Different Result — What Each Trial Moved

Trial

Post-meal glucose

Other effects

King oyster meal^[3]

Pleurotus eryngii

Kleftaki 2022 · crossover, n=19

lowered

Post-meal glucose incremental AUC was lower vs the matched control meal

Ghrelin suppressed; hunger down, fullness up. Insulin, PYY and GLP-1 unchanged.

Oyster powder meal^[2]

Pleurotus ostreatus

Dicks 2022 · IGT crossover, n=22

unchanged

Glucose, insulin and triglyceride AUCs did not differ from control

GLP-1 +17%, free fatty acids −14%, hunger −22%.

A 2025 re-analysis of the oyster-powder trial found the GLP-1 response depended on each person’s baseline gut microbiota, not the mushroom alone.^[8] The honest takeaway: the clearest, most consistent human signal is on satiety hormones and appetite, with a direct glucose drop shown so far in only one of the two species tested.

Sources: Kleftaki et al. (2022) [ref 3]; Dicks et al. (2022) [ref 2]; Klümpen et al. (2025) [ref 8].

Study 1: Oyster mushroom powder — glucose unchanged, hormones shifted. In a double-blind, randomized, controlled crossover trial, 22 adults with impaired glucose tolerance ate a meal fortified with 20 grams of oven-dried oyster mushroom (Pleurotus ostreatus) powder, supplying roughly 8 grams of beta-glucan, or a matched control meal. The primary outcome was postprandial glucose measured as area under the curve (AUC), which captures both the height and duration of the glucose response. The result: postprandial glucose AUC did not differ between the mushroom meal and the control meal. Insulin and triglyceride AUCs were also unchanged. What did move were the metabolic hormones and appetite: the satiety hormone GLP-1 rose 17% (a highly significant change), non-esterified free fatty acids fell 14%, and hunger dropped 22%.^[2] A crossover design means each participant experienced both conditions, which controls for individual variation. The honest read is that oyster mushroom powder shifted the hormonal and appetite response to a meal without lowering the glucose spike itself.

Study 2: Pleurotus eryngii (king oyster mushroom) — glucose lowered. In a separate randomized crossover trial, 19 volunteers with metabolically unhealthy obesity ate a meal containing Pleurotus eryngii or a macronutrient-matched control meal. Here the glucose signal did appear: the mushroom meal produced a lower glucose incremental AUC. It also substantially suppressed ghrelin (the hunger hormone), lowered hunger ratings, and increased fullness, while insulin, PYY, and GLP-1 did not differ.^[3] This is the clearest direct-glucose result in the human mushroom literature. The study authors attributed the effect to bioactive polysaccharides that inhibit carbohydrate-digesting enzymes and slow gastric emptying and glucose absorption.

Important context for both studies: these trials tested mushroom powder or whole mushrooms incorporated into food, not a separate capsule taken before or after eating. The mechanisms that drive a postprandial effect (viscous fiber slowing carbohydrate digestion, enzyme inhibition at the gut wall) require the fiber to be present alongside the carbohydrates. This design reflects how the biology works.

Both trials are small — 19 and 22 participants — and represent the beginning of human evidence rather than its confirmation. No larger trial has replicated either finding in a broader population, and the two studies used different species, populations, and outcome definitions, so they cannot be pooled into a single conclusion.

Mechanism 1: How Beta-Glucan Thickens the Gut and Slows Carbohydrate Absorption

The primary mechanism through which mushroom fiber reduces postprandial blood sugar is viscosity.

Soluble beta-glucan, when it reaches the small intestine, absorbs water and forms a thick, gel-like layer along the intestinal wall. This gel increases the viscosity of the intestinal contents, like adding a natural thickener to the liquid environment where digestion happens. The effect is that digestive enzymes have to work through a more viscous medium to reach carbohydrate molecules, and glucose that is released from digested carbohydrates has to diffuse through that same viscous layer before it can be absorbed into the bloodstream.

The result: the rate of glucose absorption slows. Instead of a sharp glucose spike that peaks quickly and falls, the glucose from a meal enters the bloodstream more gradually over a longer period. The total amount of glucose absorbed may not be dramatically different, but the peak concentration at any single time point is lower.

This mechanism is well-established for oat beta-glucan and explains much of why oats and barley are recommended for glycemic control. Mushroom beta-glucan operates through the same viscosity mechanism, and both the Aramabašić 2021 review and the Németh 2025 review identify it as a primary contributor to mushroom fiber's postprandial effects.^[4]

The clinical relevance: the viscosity mechanism requires sufficient soluble fiber quantity and requires it to be present in the gut alongside the carbohydrates being eaten. This is why both human trials incorporated the mushroom into the meal rather than testing it as a separate supplement.

Mechanism 2: Blocking the Enzyme That Breaks Down Starch Before Glucose Forms

The second mechanism operates through enzyme inhibition.

Alpha-glucosidase is an enzyme that sits on the surface of cells lining the small intestine. Its job is to break complex carbohydrates (starches and disaccharides) down into simple glucose molecules that can be absorbed. When alpha-glucosidase works quickly, complex carbohydrates are rapidly converted to glucose, and blood sugar rises fast.

Mushroom beta-glucans and their derivatives are thought to inhibit alpha-glucosidase activity. Beta-glucans isolated from Agaricus blazei, and the smaller oligosaccharides produced by hydrolyzing them, produced clear anti-hyperglycemic effects in diabetic animals, consistent with slowed carbohydrate breakdown and glucose release; the hydrolyzed oligosaccharides were roughly twice as active as the intact beta-glucans.^[5] The king oyster (Pleurotus eryngii) trial authors likewise attributed their postprandial glucose result in part to bioactive polysaccharides that inhibit the enzymes catalysing carbohydrate hydrolysis.^[3]

This is the same mechanism as acarbose, a medication used for type 2 diabetes that works by blocking alpha-glucosidase. The comparison is useful for context, not equivalence: acarbose is a potent enzyme inhibitor designed for pharmaceutical use, and the inhibitory effect of mushroom beta-glucan in laboratory studies is more modest. But the mechanistic overlap explains why mushrooms and acarbose produce similar postprandial effects, though at very different magnitudes.

The alpha-glucosidase inhibition mechanism complements the viscosity mechanism: one slows glucose access to the enzyme, the other reduces the enzyme's activity when glucose does reach it.

Mechanism 3: How Mushroom Fiber Shapes the Gut Bacteria That Regulate Blood Sugar

The third mechanism is slower and less immediate than the first two, but it may contribute to longer-term improvements in how the gut handles carbohydrates.

Specific gut bacteria play roles in glucose metabolism. The composition of the gut microbiome influences how quickly glucose is absorbed, how much short-chain fatty acids (like butyrate) are produced from fermented fiber, and how gut hormone signals that regulate insulin secretion are modulated. Disrupted gut bacteria (the kind associated with type 2 diabetes) are characterized by reduced populations of Bifidobacterium and Akkermansia and elevated Firmicutes-to-Bacteroidetes ratios.

Auricularia auricula-judae (wood ear mushroom) polysaccharides improved insulin resistance, glycolipid metabolism, and gut microbiota composition in a type 2 diabetes mouse model, increasing Lactobacillus and Bacteroides and acting through the AKT and AMPK signaling pathways; the authors identified the microbiota changes as part of the mechanism, not simply a secondary observation.^[6]

Human data now tie this mechanism directly back to the meal trials. A 2025 secondary analysis of the oyster mushroom powder study found that the GLP-1 response to the fortified meal depended on each participant's baseline gut microbiota: those with lower microbial evenness mounted a different hormonal response to the same mushroom fiber.^[8] This helps explain why the oyster mushroom trial moved GLP-1 rather than glucose, and it signals that individual responses to mushroom fiber are likely to vary with a person's existing microbiome.

For readers interested in how mushroom compounds reshape the gut microbiome more broadly and how that connects to blood sugar, Enoki Fiber and Postprandial Blood Sugar Response examines the postprandial angle for one specific species, and Maitake and Blood Sugar: Research on Glycemic Control covers the species with the most extensive human-relevant glucose evidence.

The prebiotic mechanism is slower than viscosity or enzyme inhibition, operating over days to weeks of consistent mushroom fiber intake rather than during a single meal. It contributes to baseline improvements in insulin sensitivity over time rather than acute postprandial attenuation.

What the Evidence Shows, and What Still Needs to Be Confirmed

The human evidence for mushroom fiber and postprandial blood sugar is real but early, and it is mixed on the specific question of glucose. Of the two 2022 human trials, only the king oyster (Pleurotus eryngii) study lowered the post-meal glucose curve directly; the oyster mushroom powder (Pleurotus ostreatus) study left glucose unchanged and instead shifted satiety hormones and free fatty acids. That split is the honest state of the direct-glucose evidence: one positive signal, one null, in small trials that have not been independently replicated in larger or more diverse populations.

The mechanistic evidence is broader. The viscosity, enzyme-inhibition, and prebiotic mechanisms each have multi-study support across species. A 2023 review of edible mushrooms in diabetes management described several converging routes — polysaccharides supporting insulin sensitivity, other bioactives acting on glucose handling and oxidative stress — through which mushroom compounds may lower blood glucose.^[7] These mechanisms are well characterized in the laboratory and in animal models; the gap is human trials that connect them to a measurable post-meal glucose benefit.

What the evidence cannot yet establish: an effective dose for a postprandial glucose effect, a species hierarchy (the two 2022 trials used different Pleurotus species, different populations, and different outcomes, and no head-to-head comparison exists), or whether any effect is meaningful for people with well-controlled diabetes on medication versus those managing glucose through lifestyle alone.

The absence of these answers reflects where the research stands, not a disqualifying limitation. Mushrooms are one of the lowest-glycemic foods available, they contain fiber with established mechanisms for slowing glucose absorption, and the human trials show a genuine but partial signal — clearer on satiety hormones than on glucose itself. That is where the evidence sits.

This article is for education, not medical advice. Mushrooms are a food, not a treatment for diabetes or insulin resistance, and nothing here should replace a clinician's guidance or prescribed medication. If you manage blood sugar, talk to your healthcare provider before making dietary changes.

For the signaling pathway mechanisms beyond fiber, specifically how mushroom beta-glucans modulate AMPK, PI3K/Akt, and GLUT4 at the cellular level, How Mushroom Beta-Glucans Modulate Insulin Signaling Pathways covers that mechanistic layer in depth. And for the broader insulin sensitivity picture across multiple species and pathways, Mushrooms and Insulin Sensitivity: Mechanisms That Improve Glucose Uptake provides the full map.

The Bottom Line

Mushrooms have a glycemic index of 10–15 and contain soluble beta-glucan fiber with three plausible routes to lower post-meal blood sugar: viscosity-mediated slowing of carbohydrate absorption, alpha-glucosidase enzyme inhibition, and prebiotic reshaping of glucose-regulating gut bacteria. The two 2022 human crossover trials are the only mushroom-specific human evidence, and they split: a king oyster (Pleurotus eryngii) meal lowered postprandial glucose incremental AUC, while an oyster mushroom (Pleurotus ostreatus) powder meal left glucose unchanged but raised GLP-1 by 17%, lowered free fatty acids, and reduced hunger. A 2025 re-analysis showed that hormonal response depended on baseline gut microbiota. The evidence is promising but early — two small trials, different species and populations, no established dose — and the mechanistic support is currently broader than the direct human glucose data.

Frequently Asked Questions

Do mushrooms cause blood sugar spikes?

No. Mushrooms have a glycemic index of approximately 10–15, which is among the lowest values of any food. A full cup of raw mushrooms contains roughly 2–3 grams of total carbohydrate, of which 1–2 grams is fiber. The net digestible carbohydrate per serving is so low that mushrooms themselves produce a negligible blood glucose response. The research question in this area is the opposite: whether mushroom fiber can reduce blood sugar spikes caused by other foods in the same meal.

What is the glycemic index of mushrooms?

Most common mushroom species have a glycemic index of approximately 10–15. This places them in the very-low-glycemic category, well below the 55-threshold for low-glycemic foods and far below common carbohydrate foods (white bread: ~75, white rice: ~72). The low GI reflects mushrooms' very low carbohydrate content and the presence of soluble fiber, which slows glucose absorption. The GI does not vary substantially across species (white button, shiitake, oyster, portobello) because all share the same fundamental macronutrient profile.

How do mushrooms prevent blood sugar spikes after eating?

Mushroom fiber is thought to act through three mechanisms. First, soluble beta-glucan forms a viscous gel in the intestine that slows carbohydrate digestion and delays glucose absorption, flattening the blood sugar curve. Second, mushroom beta-glucans and polysaccharides can inhibit alpha-glucosidase, the enzyme that breaks complex carbohydrates into simple glucose, reducing how quickly glucose is liberated for absorption. Third, mushroom polysaccharides act as prebiotics that support gut bacteria involved in glucose regulation over time. The human evidence is mixed: of the two 2022 meal trials, a king oyster (Pleurotus eryngii) meal lowered postprandial glucose incremental AUC, while an oyster mushroom powder meal did not change glucose but raised the satiety hormone GLP-1 and reduced hunger.

What type of fiber do mushrooms contain?

Mushrooms contain primarily soluble fiber in the form of beta-glucan polysaccharides, along with some chitin (insoluble fiber that forms the structural cell wall). Beta-glucan is the bioactive fraction: it is fermentable by gut bacteria (making it prebiotic), forms a viscous gel in the digestive tract (slowing glucose absorption), and inhibits alpha-glucosidase enzyme activity. Different mushroom species have different beta-glucan content by dry weight. Lion's Mane, Reishi, and Turkey Tail tend to have high beta-glucan fractions; common button mushrooms have lower concentrations. Raw mushroom fiber content is approximately 1–2 grams per cup.

Can adding mushrooms to a meal lower postprandial blood sugar?

The human evidence is mixed and species-dependent. Two human crossover trials published in 2022 tested mushrooms added to a meal. The one using Pleurotus eryngii (king oyster) whole mushroom did lower postprandial glucose incremental AUC compared to a matched control meal. The one using oyster mushroom (Pleurotus ostreatus) powder did not change postprandial glucose AUC, but it raised the satiety hormone GLP-1 by 17%, lowered free fatty acids, and reduced hunger. So adding mushrooms to a meal may help — clearly for appetite and satiety hormones, and for glucose in at least one species — but the direct glucose benefit is not yet consistent across studies. Both trials tested mushroom incorporated into food rather than taken as a separate supplement, reflecting how the fiber mechanisms work.

Are mushrooms low glycemic?

Yes. Mushrooms are very low glycemic with a GI of approximately 10–15, compared to a threshold of 55 for foods classified as low-glycemic. This is because mushrooms contain very little digestible carbohydrate and a meaningful proportion of their carbohydrate fraction is indigestible fiber. For people managing blood sugar, mushrooms are one of the foods with the smallest glucose impact per serving. The more relevant question for blood sugar management is whether mushroom fiber can also reduce the glycemic effect of other foods eaten in the same meal. The early human evidence from 2022 suggests it can.

Sources & References

1. 1RTHM-02157·Németh, Zsuzsanna et al. (2025). “The Importance of Edible Medicinal Mushrooms and Their Potential Use as Therapeutic Agents Against Insulin Resistance..” International journal of molecular sciences.Study breakdown →PubMed →↩
2. 2RTHM-00753·Dicks, Lisa et al. (2022). “Fortifying a meal with oyster mushroom powder beneficially affects postprandial glucagon-like peptide-1, non-esterified free fatty acids and hunger sensation in adults with impaired glucose tolerance: a double-blind randomized controlled crossover trial..” European journal of nutrition.Study breakdown →PubMed →↩
3. 3RTHM-01551·Kleftaki, Stamatia-Angeliki et al. (2022). “Pleurotus eryngii improves postprandial glycaemia, hunger and fullness perception, and enhances ghrelin suppression in people with metabolically unhealthy obesity..” Pharmacological research.Study breakdown →PubMed →↩
4. 4RTHM-01322·Aramabašić Jovanović, Jelena et al. (2021). “The Effects of Major Mushroom Bioactive Compounds on Mechanisms That Control Blood Glucose Level..” Journal of fungi (Basel.Study breakdown →PubMed →↩
5. 5RTHM-00082·Kim, Yea-Woon et al. (2005). “Anti-diabetic activity of beta-glucans and their enzymatically hydrolyzed oligosaccharides from Agaricus blazei..” Biotechnology letters.Study breakdown →PubMed →↩
6. 6RTHM-00728·Xu, Nuo et al. (2021). “Auricularia auricula-judae (Bull.) polysaccharides improve type 2 diabetes in HFD/STZ-induced mice by regulating the AKT/AMPK signaling pathways and the gut microbiota..” Journal of food science.Study breakdown →PubMed →↩
7. 7RTHM-00850·Shamim, Mohammad Zaki et al. (2023). “Exploring Edible Mushrooms for Diabetes: Unveiling Their Role in Prevention and Treatment..” Molecules (Basel.Study breakdown →PubMed →↩
8. 8RTHM-02111·Klümpen, Linda et al. (2025). “GLP-1 Responses to a Single Meal Fortified With Oyster Mushroom Powder in Adults With Impaired Glucose Tolerance Depend on the Gut Microbiota Composition Before the Meal..” Molecular nutrition & food research.Study breakdown →PubMed →↩